Eating Disorders News and Research

Latest Eating Disorders News and Research

Research provides new insights into eating disorders in Native Americans

The research, published in the International Journal of Eating Disorders, provides new insights into the extent to which Native American populations experience eating disorders, revealing that women are more likely to report behavioral symptoms then men, while challenging views that NA men and ethnically white men will experience different psychological symptoms.

7 Jan 2011

Way of experiencing internal state of body influences perception of body from the outside

A new study, led by Dr Manos Tsakiris from Royal Holloway, University of London, suggests that the way we experience the internal state of our body may also influence how we perceive our body from the outside, as for example in the mirror. The research appears today (5 January) in the Proceedings of the Royal Society B.

5 Jan 2011

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

Celgene International Sàrl announced regulatory submissions for its blood cancer therapies REVLIMID (lenalidomide) and ISTODAX (romidepsin).

5 Jan 2011

Vicus initiates VT-122 Phase 2 trial in advanced liver cancer, systemic inflammation and cachexia

Vicus Therapeutics, LLC, today announced the initiation of a Phase 2 trial evaluating VT-122, a novel investigational combination of etodolac and propranolol, and Nexavar® (sorafenib) tablets, as a potential new treatment option for patients with advanced liver cancer (hepatocellular carcinoma), systemic inflammation and cachexia.

28 Dec 2010

Fat or obese – What’s in a name?

The question of whether the term ‘fat’ is more appropriate than ‘obese’ was raised in an Australian study that confirmed the former is the “lesser of two evils”. The study from University of NSW study which looked at public perceptions surrounding these words has found that, while both are unwelcome, obese was viewed more negatively.

13 Dec 2010

Alkermes announces preliminary results from ALKS 33 Phase 2 study in alcohol dependence

Alkermes, Inc. today announced preliminary results from a phase 2 clinical study of ALKS 33, one of Alkermes' proprietary candidates for the treatment of reward disorders and other central nervous system (CNS) disorders. The 12-week study was designed to assess the safety and efficacy of daily oral administration of three different dose levels of ALKS 33 compared to placebo in 400 alcohol dependent patients.

9 Dec 2010

Data from comparative REVLIMID study in multiple myeloma presented at 52nd ASH

Celgene International Sàrl today announced that data from a randomised clinical study conducted by the Eastern Cooperative Oncology Group (ECOG) were presented at the 52nd Annual Meeting of the American Society of Hematology comparing REVLIMID® (lenalidomide) plus low-dose dexamethasone (Rd) to lenalidomide plus high-dose dexamethasone (RD) in both younger and older newly-diagnosed multiple myeloma patients (NDMM).

7 Dec 2010

Pivotal Phase II study data of romidepsin in relapsed PTCL presented at ASH 2010

Celgene International Sàrl today announced that data from a pivotal Phase II, multicenter, international, open-label study of romidepsin (ISTODAX) in progressive or relapsed PTCL following prior systemic therapy were presented at the 52nd American Society of Hematology Annual Meeting.

6 Dec 2010

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Celgene International Sàrl (NASDAQ: CELG) announced that data evaluating combination therapy REVLIMID® (lenalidomide) and dexamethasone in patients with high-risk asymptomatic smoldering multiple myeloma were presented during the American Society of Hematology's annual meeting. The study reported REVLIMID and dexamethasone prolonged time to progression.

6 Dec 2010

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Celgene International Sàrl announced that clinical data from two investigational studies evaluating the use of REVLIMID (lenalidomide) either with rituximab or following a rituximab-containing regimen in patients with chronic lymphocytic leukaemia were presented at the 52nd American Society of Hematology annual meeting.

6 Dec 2010

Zometa improves OS, PFS in newly diagnosed multiple myeloma patients: Phase III study

A newly published study in the Lancet suggested that a first-line treatment regimen including Zometa (zoledronic acid) significantly improved overall survival and progression-free survival in newly diagnosed multiple myeloma patients compared with a regimen that included oral clodronate. The impact on survival was independent of the effect of Zometa on bone complications (also known as skeletal-related events or SREs).

4 Dec 2010

European Commission approves Pfizer's SUTENT for pancreatic neuroendocrine tumors

Pfizer Inc. announced today that the European Commission has approved SUTENT (sunitinib malate) for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumors (NET) with disease progression in adults.

2 Dec 2010

Timberline Knolls psychiatrist recommends patients to receive specialized care for co-occurring disorder

According to the American Psychiatric Association, at least three percent of the United States population has a co-occurring disorder, yet only eight percent of those suffering receive specialized treatment for both their mental illness and substance abuse disorders.

2 Dec 2010

Eating Disorder Hope partners with MyPyramid to help eating disorder sufferers

Eating Disorder Hope, a respected independent resource for sufferers of anorexia, bulimia and overeating disorders, has partnered with MyPyramid to help eating disorder sufferers find nutritional and healthy lifestyle support.

24 Nov 2010

Scientists identify gene variants associated with eating disorder

Scientists at The Children's Hospital of Philadelphia have identified both common and rare gene variants associated with the eating disorder anorexia nervosa.

20 Nov 2010

Pfizer's Phase 3 AXIS 1032 trial for metastatic renal cell carcinoma meets primary endpoint

Pfizer Inc. announced today that the Phase 3 AXIS 1032 trial (A4061032), studying the investigational compound axitinib in previously treated patients with metastatic renal cell carcinoma (mRCC), has met its primary endpoint, demonstrating that axitinib significantly extended progression-free survival when compared to sorafenib, in the study population.

20 Nov 2010

Acceleron presents ACE-041 interim results for advanced cancer at EORTC-NCI-AACR Symposium

Acceleron Pharma, Inc., a biopharmaceutical company developing novel protein therapeutics that regulate the growth and development of tissues and cells, including muscle, bone, red blood cells, and vasculature, today announced the presentation of interim results from the first-in-human clinical study of ACE-041 in patients with advanced cancer at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Berlin, Germany.

20 Nov 2010

MK-4827 drug candidate shows promising anti-tumour activity in first human trial

A new drug that targets proteins responsible for helping cancer cells to repair damage to their DNA has shown promising anti-tumour activity in its first trial in humans.

18 Nov 2010

Alkermes's ALKS 33 drug candidate offers potential treatment for multiple disease indications

Alkermes, Inc. today announced the presentation of promising preclinical results for its proprietary opioid modulator, ALKS 33, showing the drug candidate's potential in multiple disease indications.

17 Nov 2010

WaterBrook Press releases third edition of Hope, Help and Healing for Eating Disorders

WaterBrook Press recently released the third edition of Hope, Help and Healing for Eating Disorders, A Whole-Person Approach to Treatment of Anorexia, Bulimia and Disorder Eating. The newest edition of this 1995 bestseller on overcoming anorexia, bulimia and other eating disorders from Dr. Gregory L. Jantz, PhD, with Ann McMurray, features the most up-to-date information on body image, food addiction, nutrition and more.

15 Nov 2010

Eating Disorders News and Research

Latest Eating Disorders News and Research

Research provides new insights into eating disorders in Native Americans

Way of experiencing internal state of body influences perception of body from the outside

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

Vicus initiates VT-122 Phase 2 trial in advanced liver cancer, systemic inflammation and cachexia

Fat or obese – What’s in a name?

Alkermes announces preliminary results from ALKS 33 Phase 2 study in alcohol dependence

Data from comparative REVLIMID study in multiple myeloma presented at 52nd ASH

Pivotal Phase II study data of romidepsin in relapsed PTCL presented at ASH 2010

Study: REVLIMID and dexamethasone for high-risk smoldering multiple myeloma reduce risk of disease progression

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Zometa improves OS, PFS in newly diagnosed multiple myeloma patients: Phase III study

European Commission approves Pfizer's SUTENT for pancreatic neuroendocrine tumors

Timberline Knolls psychiatrist recommends patients to receive specialized care for co-occurring disorder

Eating Disorder Hope partners with MyPyramid to help eating disorder sufferers

Scientists identify gene variants associated with eating disorder

Pfizer's Phase 3 AXIS 1032 trial for metastatic renal cell carcinoma meets primary endpoint

Acceleron presents ACE-041 interim results for advanced cancer at EORTC-NCI-AACR Symposium

MK-4827 drug candidate shows promising anti-tumour activity in first human trial

Alkermes's ALKS 33 drug candidate offers potential treatment for multiple disease indications

WaterBrook Press releases third edition of Hope, Help and Healing for Eating Disorders

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Eating Disorders News and Research

Latest Eating Disorders News and Research

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in